HOME >> MEDICINE >> NEWS
Health providers could save billions without compromising health care says drug study

w drug once they'd switched.

The patient who was switched back to atorvastatin reported experiencing visual symptoms at night on simvastatin.

The clinical outcome ten months after the switch was positive. There was no significant change in blood cholesterol levels and no new diagnoses of ischaemic heart disease or cerebrovascular accidents among the 69 patients who had switched.

137 patients were receiving the blood pressure drug Iosartan. 26 were excluded by the practice pharmacist or doctors and six patients said they didn't want to switch. Of the 115 who switched to candesartan, 108 (94 per cent) stayed on the drug.

The reasons for switching back to the original blood pressure drug ranged from one case of chest tightness to patients requesting a change or feeling anxious about their treatment.

At the ten-month review, no patients had suffered adverse events related to the switch.

The authors have stressed the importance of carefully selecting patients based on sound clinical criteria and making sure that patients are happy with the switch and understand the reasons behind it.

"Indiscriminate switching policies in patients previously well controlled may have inherent risks to those patients, either as a direct result of the medication change or indirectly if the change subsequently affects their relationship with medical services or compliance" adds Juliet Usher-Smith.

"This clearly didn't happen in this study, where patients were carefully selected and, with the exception of a few on blood pressure medication, were happy with the change. "

No adverse events were attributed to the change in medication and the net savings to the practice were significant.

By switching the medication of 185 patients, the practice saved 26,000 - just under two per cent of its annual 1.3 million drugs budget for more than 9,000 registered patients.

The savings were ca
'"/>

Contact: Annette Whibley
wizard.media@virgin.net
Blackwell Publishing Ltd.
17-Jan-2007


Page: 1 2 3

Related medicine news :

1. RAND, Health Dialog form alliance to create tools to evaluate health-care quality and efficiency
2. HealthGrades study: Bariatric surgery patients have fewer complications at high-volume hospitals
3. Health reform bills could improve quality and efficiency, but fall short of national plan
4. Support for Childrens Health and Medicare Protection Act given to House leaders by ACP
5. Stevens Roundtable: Health, Technology & Society, July 11
6. Poorer countries could struggle to implement new International Health Regulations
7. Healthy body weight throughout adulthood may help delay disability
8. Cigarette use may explain asthma epidemic in children, says Mailman School of Public Health study
9. Healthy children with smoking parents arent really so healthy
10. American College of Physicians commends introduction of Bipartisan Health CARE Act
11. ACP enthusiastically supports introduction of Bipartisan Health CARE Act

Post Your Comments:
(Date:5/5/2015)... Alachua, FL (PRWEB) May 05, 2015 ... technology company focused on the $1.6 billion peripheral nerve ... the first quarter ended March 31, 2015 compared to ... “The market’s continued adoption of our proprietary portfolio of ... Nerve Connector and AxoGuard® Nerve Protector – and our ...
(Date:5/5/2015)... 2015 Leveraging the industry-leading technology found ... an experienced team of fertility specialists are committed to ... around the globe. , “We’re honored that Maternity Health ... a global leader in reproductive medicine. The clinic offers ... in the world who play an important role in ...
(Date:5/5/2015)... global lab automation market is expected to reach $5,105.7 ... an estimated CAGR of 6.7% from 2015 to 2020. ... basis of equipment and software, application, type of automation, ... Lab Automation Market is classified into clinical diagnostics, drug ... a major application of the lab automation market. Developing ...
(Date:5/5/2015)... 05, 2015 Hundreds of ... on behalf of men who allegedly suffered ... of prescription testosterone replacement therapies continue to ... underway in U.S. District Court, Northern District ... May 1st, defendants AbbVie, Inc., Auxilium Pharmaceuticals, ...
(Date:5/5/2015)... Viverae®, a health management and engagement ... multinational developer, manufacturer and marketer of innovative, life-enhancing ... oncology and surgical specialty products, as the recipient ... Award recognizes outstanding achievement in the design and ... client base. , Viverae reviewed the employee wellness ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2
(Date:5/5/2015)... 2015 Ardelyx, Inc. (NASDAQ: ARDX ... gastrointestinal, and metabolic diseases, today announced that a ... Stage 3 chronic kidney disease patients with type ... the primary endpoint of decreasing the urinary albumin-creatinine ... placebo. Ardelyx formed a partnership ...
(Date:5/5/2015)... -- (Family Features) Which health screenings and exams are ... monitoring your weight, cholesterol, and blood pressure is probably ... vision care? Photo - http://photos.prnewswire.com/prnh/20150505/213909 ... they often start to notice small changes in their ... performance. Whether having difficulty reading a book or working ...
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... addition of the "Electro Surgical Market" ... electrosurgical market is expected to achieve a CAGR ... surgery offer huge benefits for patients as well ... surgery infections, condensed visible marks, bleeding control and ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6Eye Care as You Age 2Eye Care as You Age 3Eye Care as You Age 4Global Electro Surgical Market 2015 2
Cached News: